In CLL cells, we observed reduced expression of the ibrutinib target BTK, of CD52 (a CLL disease activity marker29), and of CD27 (a regulator of B-cell activation30). This evidence concerns the gene CD27 and B-cell chronic lymphocytic leukemia.